

RESEARCH ARTICLE

Circulating Interleukin-6 Mediates PM_{2.5}-Induced Ovarian Injury by Suppressing the PPAR γ Pathway

Yingying Chen^{1,2†}, Jinjin Zhang^{1,3†}, Tianyu Zhang^{1,3}, Yaling Wu^{1,3}, Yueyue Xi^{1,3}, Tong Wu^{1,3}, Mo Li^{1,3}, Yan Li^{1,3*}, Su Zhou^{1,3*}, Mingfu Wu^{1,3*}, and Shixuan Wang^{1,3*}

¹Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

²Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China. ³Key Laboratory of Cancer Invasion and Metastasis (Ministry of Education), Hubei Key Laboratory of Tumor Invasion and Metastasis, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

*Address correspondence to: shixuanwang@tjh.tjmu.edu.cn (S.W.); wu_mingfu@tjh.tjmu.edu.cn (M.W.); suzhou@tjh.tjmu.edu.cn (S.Z.); liyan@tjh.tjmu.edu.cn (Y.L.)

†These authors contributed equally to this work.

Exposure to airborne fine particulate matter (PM_{2.5}) is strongly associated with poor fertility and ovarian damage. However, the mechanism underlying this remains largely unclear. Here, we found that PM_{2.5} markedly impaired murine ovarian reserve, decreased hormone levels, and aggravated ovarian inflammation. Circulating interleukin-6 (IL-6) was elevated in PM_{2.5}-exposed mice and was further confirmed to mediate this damage by IL-6 recombinant protein intervention. PM_{2.5} exposure led to increased alveolar macrophage infiltration in the lungs. However, alveolar macrophage clearance with clodronate liposomes could not fully reverse the elevated IL-6 levels and ovarian injury, suggesting that alveolar macrophages were probably not the only source of circulating IL-6. Further experiments indicated that IL-6 mainly targeted ovarian theca–interstitial cells and impaired testosterone synthesis via suppressing the peroxisome proliferator-activated receptor γ (PPAR γ) pathway. In addition, apoptosis of granulosa cells and restriction of follicular growth were observed in co-cultures with IL-6-treated theca–interstitial cells, which could be further reversed by the PPAR γ agonist. Moreover, IL-6-neutralizing antibodies ameliorated PM_{2.5}-induced ovarian damage. Notably, increased levels of circulating IL-6 were observed in premature ovarian aging patients and were inversely associated with their ovarian function. In summary, our findings offer a mechanistic explanation for PM_{2.5}-induced ovarian dysfunction and verify IL-6 as a biomarker and potential therapeutic target.

Introduction

Fine particulate matter (PM_{2.5}) pollution is an unavoidable environmental problem worldwide, both presently and in the future. Due to its wide distribution, small particle size, and complex composition, its harmful health effects are of increasing concern [1,2]. The International Agency for Research on Cancer classified PM_{2.5} as a human class I carcinogen in 2013 [3], and it was responsible for up to 1.8 million deaths in 13,160 urban areas worldwide in 2019 [4]. PM_{2.5} has been linked to various adverse health outcomes, including respiratory and cardiovascular diseases [5–7], stroke [6–8], Alzheimer's disease [9], diabetes [6,10], and obesity [11,12]. Consequently, the multi-organ injury caused by PM_{2.5} has attracted considerable attention.

Accumulating evidence suggests that PM_{2.5} exposure is associated with poor fertility [13,14] and adverse pregnancy outcomes [15,16]. A large prospective cohort study showed that nurses exposed to PM_{2.5} in midlife experienced menopause at an earlier age [17]. The antral follicle count (AFC) is widely used clinically to assess ovarian reserve. Data from 632 women at the Massachusetts Reproductive Center showed a negative association between PM_{2.5} concentration and AFC [18]. Animal studies have suggested that exposure to PM_{2.5} affects ovarian hormone secretion and oocyte maturation, and metal imbalance and steroid synthesis disruption are involved in the process [19]. However, the detailed mechanisms and key molecules responsible for systematic PM_{2.5}-exposure-induced ovarian injury remain largely unclear, hampering the development of strategies to protect ovarian function.

Citation: Chen Y, Zhang J, Zhang T, Wu Y, Xi Y, Wu T, Li M, Li Y, Zhou S, Wu M, et al. Circulating Interleukin-6 Mediates PM_{2.5}-Induced Ovarian Injury by Suppressing the PPAR γ Pathway. *Research* 2024;7:Article 0538. <https://doi.org/10.34133/research.0538>

Submitted 22 August 2024

Revised 30 October 2024

Accepted 5 November 2024

Published 5 December 2024

Copyright © 2024 Yingying Chen et al. Exclusive licensee Science and Technology Review Publishing House. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License (CC BY 4.0).

Our prior research has shown that the soluble fractions of PM_{2.5} exacerbated ovarian damage, which is associated with increased oxidative stress and inflammation [20]. However, direct evidence of PM_{2.5} deposition in ovarian tissues is lacking. The observation and quantification of real-time PM_{2.5} deposition in the ovaries are hindered by the limited blood flow to these tissues. Previous studies have indicated that PM_{2.5} exposure can cause systemic inflammation [21–23], a condition closely linked to ovarian dysfunction [24,25]. Elevated concentrations of circulating cytokines, including interleukin-6 (IL-6), interleukin-1 beta, interleukin-10, interleukin-12, interleukin-17, and tumor necrosis factor α , are well-recognized indicators of systemic inflammation. Consequently, we hypothesize that these elevated levels of circulating inflammatory cytokines may contribute to PM_{2.5}-induced ovarian damage.

This study verified the ovarian damage caused by PM_{2.5}, identified the major mediators, and elucidated the target cells and underlying molecular mechanisms. Notably, we demonstrated the therapeutic potential of IL-6-neutralizing antibodies (IL-6 Abs) against such damage. Moreover, we observed a negative correlation between IL-6 levels and ovarian function in women. Our findings provide novel insights into how PM_{2.5} damages the ovaries and confirm IL-6 as a key mediator and potential therapeutic target for PM_{2.5}-induced ovarian damage.

Results

Damages of the ovarian reserve and steroid synthesis induced by PM_{2.5} exposure

To evaluate the effects of exposure to PM_{2.5} on ovarian function, C57BL/6 mice were exposed to PM_{2.5} suspension (8 mg/kg body weight [bw]) via intratracheal dripping every 2 d (equivalent to the human exposure concentration of 35 $\mu\text{g}/\text{m}^3$) (Fig. 1A). The serum anti-Müllerian hormone (AMH) concentration significantly decreased after exposure to PM_{2.5} (Fig. 1B). Compared with those of the control (CON) group, the number of primordial follicles, secondary follicles, and total healthy follicles in the PM_{2.5}-treated group were significantly decreased (Fig. 1C and D), while the number of atretic follicles was significantly increased (Fig. 1D). The percentages of irregular estrous cycles in the CON and PM groups were 25% and 72%, respectively (Fig. 1E). As shown in Fig. 1F to H, exposure to PM_{2.5} significantly decreased the concentration of serum estradiol (E2) and testosterone (T), whereas no significant differences in serum follicle-stimulating hormone (FSH) levels were observed between the CON and PM groups. These results indicate that PM_{2.5} exposure diminishes the ovarian reserve and disrupts steroid synthesis.

We examined the expression of related genes to elucidate the molecular mechanisms underlying the disrupted steroid synthesis. Western blot analysis showed that exposure to PM_{2.5} significantly decreased the expression of StAR, CYP17A1, CYP19A1, and HSD17B1 (Fig. 1I and J). Free cholesterol is directly used for steroid hormone synthesis, whereas cholesterol esters, stored in lipid droplets, cannot be directly used for hormone synthesis [26]. Transmission electron microscopy (TEM) revealed that PM_{2.5} induced a large accumulation of lipid droplets in theca-interstitial cells (TICs) (Fig. 1K), potentially affecting hormone synthesis. Our results further demonstrated that exposure to PM_{2.5} down-regulated the expression of cholesterol-metabolism-related genes, including HMGCR,

HMGCS1, SR-B1, and HSL. Together, these findings suggest that PM_{2.5} exposure disrupts steroid biosynthesis in murine ovaries.

Elevation of circulating IL-6 mediated PM_{2.5}-induced ovarian injury

For the mechanism investigation of PM_{2.5}-induced ovarian injury, RNA sequencing analysis was conducted. Gene Ontology enrichment analysis showed that the genes down-regulated were enriched in cellular hormone metabolic processes mainly (Fig. S1A), whereas the up-regulated genes were primarily concentrated in the acute phase response and inflammatory response (Fig. S1B). These findings suggested that inflammation may be involved in PM_{2.5}-induced ovarian injury. Further examination of inflammatory factors in the ovaries utilizing the Luminex liquid suspension chip showed an increase in interleukin-13, IL-6, interleukin-17A, and other factors in PM_{2.5}-exposed ovaries (Fig. S1C and D). As PM_{2.5} is known to cause systemic inflammation [21–23], the elevated levels of circulating cytokines induced by PM_{2.5} may be an important factor contributing to ovarian inflammation. Serum Luminex liquid suspension chip analysis further revealed a significant increase in circulating IL-6 and keratinocyte-derived chemokine after exposure to PM_{2.5} (Fig. S1E and F). Combining the analyses of ovarian and serum cytokines, it was evident that IL-6 levels were significantly elevated (Fig. 2A), which suggests its key role in mediating PM_{2.5}-induced ovarian injury.

To determine whether circulating IL-6 mediates PM_{2.5}-induced ovarian injury, mice were treated with IL-6 recombinant protein (rm IL-6) (Fig. 2B). The results showed that rm IL-6 increased serum IL-6 levels (Fig. 2C); decreased serum AMH levels (Fig. 2D); reduced the number of primordial follicles, secondary follicles, and total healthy follicles; and increased the number of atretic follicles (Fig. 2E and F). The proportion of irregular estrous cycles was significantly increased. The levels of serum E2 and T were lower in the rm IL-6 group than in the CON group (Fig. 2H and I). In contrast, serum FSH levels were not significantly different between the 2 groups. The expression of hormone-synthesis-related genes also decreased (Fig. 2K to M). In summary, these findings imply that circulating IL-6 may mediate PM_{2.5}-induced ovarian injury.

Alveolar macrophages were probably not the major source of circulating IL-6

Previous research studies have revealed that acute PM_{2.5} exposure induces IL-6 secretion due to alveolar macrophages, resulting in elevated circulating IL-6 [27–30]. To clarify whether circulating IL-6 was derived from alveolar macrophages, we identified the expression of IL-6 in alveolar macrophages and conducted alveolar macrophage clearance experiments. Hematoxylin and eosin (H&E) staining of murine lungs showed that PM_{2.5} exposure led to a disrupted alveolar structure, a thickened alveolar septa, and increased immune cell infiltration (Fig. S2A). Immunohistochemistry (IHC) staining further suggested that PM_{2.5} induced alveolar macrophage infiltration (Fig. S2B to E). These results suggest that alveolar macrophages are a potential source of elevated circulating IL-6 levels.

To verify this hypothesis, we performed alveolar macrophage clearance with clodronate liposomes (CLS) and investigated whether it could reverse the elevated circulating IL-6 levels and




Fig. 1. PM_{2.5} exposure induced ovarian injury. (A) Scheme of the animal study for assessing the effect of PM_{2.5} exposure on ovarian function. (B) The serum anti-Müllerian hormone (AMH) level in PM_{2.5}-exposed mice (n = 8 mice/group, 2-tailed Student t test). (C) Ovarian hematoxylin and eosin (H&E) staining image from PM_{2.5}-exposed mice. (D) Follicle counting results according to ovary serial sections (n = 5 mice/group, 2-tailed Student t test). (E) The proportion of regular or irregular estrous cycles in PM_{2.5}-exposed mice (n = 8 mice/group, chi-square test). (F to H) The serum hormone level of mice exposed to PM_{2.5} (n = 9 to 13 mice/group, 2-tailed Student t test). (I and J) Protein expression of the hormone synthesis rate-limiting enzyme in ovaries from PM_{2.5}-exposed mice detected by Western blot (n = 3 biological replicates/group, 2-tailed Student t test). (K) Transmission electron microscopy of ovarian tissue from mice exposed to PM_{2.5}. Blue arrows indicate mitochondria. (L and M) Protein expression of cholesterol-metabolism-related genes in ovaries from PM_{2.5}-exposed mice detected by Western blot (n = 3 biological replicates/group, 2-tailed Student t test). PMF, primordial follicle; PF, primary follicle; SF, secondary follicle; ANF, antral follicle; THF, total healthy follicle; ATF, atretic follicle; CL, corpus luteum; E2, estradiol; T, testosterone; FSH, follicle-stimulating hormone; N, nucleus; L, lipid droplet.




Fig. 2. Circulating interleukin-6 (IL-6) mediated PM_{2.5}-induced ovarian injury. (A) Venn plots of elevated cytokines in the circulation and ovaries of mice exposed to PM_{2.5}. (B) Scheme of the animal study for assessing the effect of IL-6 on ovarian function. (C) The serum IL-6 levels of mice upon administration of IL-6 recombinant protein (rm IL-6) ($n = 9$ mice/group, 2-tailed Student *t* test). (D) The serum AMH level of mice treated with rm IL-6 ($n = 11$ mice/group, 2-tailed Student *t* test). (E) Ovarian H&E staining images of mice treated with rm IL-6. (F) Follicle counting results according to ovary serial sections ($n = 5$ mice/group, 2-tailed Student *t* test). (G) The proportion of regular or irregular estrous cycles of mice treated with rm IL-6 ($n = 11$ mice/group, chi-square test). (H to J) The serum hormone level of mice treated with rm IL-6 ($n = 7$ to 11 mice/group, 2-tailed Student *t* test). (K to M) Protein expression of hormone-synthesis-related genes in ovaries from rm IL-6-treated mice detected by Western blot ($n = 3$ biological replicates/group, 2-tailed Student *t* test). rm IL-6, IL-6 recombinant protein; KC, keratinocyte-derived chemokine.

ovarian injury caused by PM_{2.5} (Fig. 3A). The results demonstrated that CLS reversed PM_{2.5}-induced alveolar macrophage infiltration and elevated IL-6 levels in lung tissues (Fig. 3B to E); however, a little change was observed in circulating IL-6 levels

(Fig. 3F). Furthermore, PM_{2.5}-induced ovarian injury was not alleviated by CLS treatment (Fig. 3G to M). Therefore, these results indicate that alveolar macrophages are probably not a major source of circulating IL-6.




Fig. 3. Alveolar macrophages were probably not the major source of circulating IL-6. (A) Scheme of the animal study for assessing whether alveolar macrophage clearance can reverse PM_{2.5}-induced elevated circulating IL-6 and ovarian injury. (B) Representative images of anti-F4/80 staining in lungs from mice exposed to PM_{2.5}, with or without clodronate liposome (CLS) administration. (C) The number of macrophages in murine lungs according to anti-F4/80 staining (n = 3 mice/group, one-way analysis of variance [ANOVA]). (D to F) The IL-6 levels in the lung (n = 5 mice/group), bronchoalveolar lavage fluid (BALF) (n = 9 to 10 mice/group), and serum (n = 6 to 8 mice/group) of mice exposed to PM_{2.5} with or without CLS administration (one-way ANOVA). (G) The serum AMH level of mice exposed to PM_{2.5} with or without CLS administration (n = 8 to 11 mice/group, one-way ANOVA). (H) Ovarian H&E staining images of mice exposed to PM_{2.5} with or without CLS administration. (I) Follicle counting results according to ovary serial sections (n = 5 mice/group, one-way ANOVA). (J) The proportion of regular or irregular estrous cycles of mice exposed to PM_{2.5} with or without CLS administration (n = 11 mice/group, chi-square test). (K to M) The serum hormone level of mice exposed to PM_{2.5} with or without CLS administration (n = 7 to 11 mice/group, one-way ANOVA). CLS, clodronate liposomes (one-way ANOVA).

Disruption of T synthesis in TICs by IL-6 through the PPAR γ pathway

The molecular mechanism of IL-6-mediated ovarian injury caused by PM_{2.5} was further investigated. Single-cell RNA sequencing of murine ovaries showed that the IL-6 receptor (IL-6R α) was highly expressed in TICs and almost absent in granulosa cells (GCs) (Fig. 4A). The IHC of ovarian tissues further indicated that IL-6R α was specifically expressed in TICs (Fig. 4B). Therefore, we hypothesized that TICs are direct targets of IL-6.

We then explored the role of IL-6 on TICs. Mouse primary TICs treated with rm IL-6 showed no obvious effect on cell proliferation (Fig. S3A and B); however, they reduced T synthesis and decreased hormone-synthesis-related gene expression—*Hsd17b1*, *Cyp17a1*, and *Hsl* (Fig. 4C and Fig. S3C to L). We further explored the molecular mechanisms by which IL-6 affects T synthesis in TICs. Transcriptome sequencing revealed that the genes down-regulated in IL-6-treated TICs were enriched in the RIG-I-like signaling pathway, the peroxisome proliferator-activated receptor (PPAR) signaling pathway, the adenosine 5'-monophosphate-activated protein kinase signaling pathway, etc. (Fig. 4D). Among them, the PPAR pathway is involved in the regulation of lipid metabolism, adipocyte differentiation, glycogen heterodimerization, and cell survival [31,32], which aroused our interest for further study. Specifically, IL-6 was found to result in a notable reduction in peroxisome proliferator-activated receptor γ (PPAR γ) transcript and protein expression in TICs and ovaries (Fig. 4E to K). Additionally, a PPAR γ agonist, GW1929, reversed the IL-6-induced reduction of T and expression of hormone-synthesis-related genes HSD17B1, CYP17A1, and HSL (Fig. 4L to N). These findings suggest that IL-6 disrupts T synthesis in TICs through the PPAR γ pathway.

Inhibition of GC E2 synthesis and follicular growth by IL-6-treated TICs

According to the 2-cell theory of hormone synthesis, androgens synthesized by TICs are the raw materials for estrogen biosynthesis by GCs [33–35]. To clarify the effect of IL-6 on hormone synthesis by GCs, GCs were co-cultured with a conditioned medium of IL-6-treated TICs (Fig. 5A). We found that the conditioned medium resulted in reduced E2 synthesis and decreased HSD17B1 and CYP19A1 expression in GCs (Fig. 5B to D). It also induced GC apoptosis (Fig. 5C to F), which partially explains the cause of follicular atresia caused by PM_{2.5}.

In order to ascertain the impact of IL-6 on follicular growth, we co-cultured preantral follicles with a conditioned medium of IL-6-treated TICs (Fig. 5G). The results showed that IL-6-treated TICs restricted follicular growth (Fig. 5H and I); however, no significant effect was observed on follicular atresia (Fig. 5J), which might be related to the duration of the intervention. Furthermore, the PPAR γ agonist reversed the effects induced by IL-6 (Fig. 5A to I). These results suggest that IL-6 decreases GC E2 synthesis and restricts follicular growth via TICs.

Alleviation of PM_{2.5}-induced ovarian injury by IL-6 Abs

The above results showed that IL-6 mediates ovarian injury caused by PM_{2.5} exposure. To determine whether IL-6 Abs could ameliorate PM_{2.5}-induced ovarian injury, mice were treated with IL-6 Abs (Fig. 6A). The results showed that IL-6 Abs successfully reversed the elevated circulating IL-6 levels caused by PM_{2.5} exposure (Fig. 6B) and alleviated the decline

in serum AMH levels and healthy follicle counts (Fig. 6C to E). Moreover, IL-6 Abs ameliorated PM_{2.5}-induced estrous cycle disorder, serum E2 and T level decline (Fig. 6F to I), and hormone-synthesis-related gene and PPAR γ disruption (Fig. 6J to N). Overall, these results indicate that IL-6 Abs alleviate PM_{2.5}-induced ovarian injury, and IL-6 may represent a therapeutic target for the treatment of ovarian damage induced by PM_{2.5}.

Negative correlation of circulating IL-6 levels with ovarian function in women

Premature ovarian insufficiency (POI) and diminished ovarian reserve (DOR) are different phenotypes of premature ovarian aging. The relationship between circulating IL-6 levels and ovarian function was explored in 215 participants consisting of healthy women ($n = 118$), women with DOR ($n = 50$), and women with POI ($n = 47$) (Fig. 7A). The association between serum IL-6 and ovarian steroid hormone levels was analyzed. Serum IL-6 levels were negatively associated with serum levels of AMH ($r = -0.4020$, $P < 0.0001$; Fig. 7B) and T ($r = -0.1498$, $P = 0.0289$; Fig. 7D) and positively associated with serum FSH levels ($r = 0.4378$, $P < 0.0001$; Fig. 7E). No significant association between serum IL-6 levels and concentrations of serum E2 was identified ($r = -0.1101$, $P = 0.1074$; Fig. 7C). Additionally, serum IL-6 levels were significantly higher in patients with DOR and POI than in healthy women ($P < 0.0001$; Fig. 7F). These results demonstrate a negative correlation between circulating IL-6 levels and ovarian function, which suggests that circulating IL-6 may serve as a biomarker for assessing ovarian function.

Discussion

In this study, we demonstrated that PM_{2.5} exposure induces ovarian injury by elevating circulating IL-6, which may not originate from alveolar macrophages alone. Neutralization of IL-6 ameliorates PM_{2.5}-induced ovarian damage. We also revealed that circulating IL-6 is negatively correlated with ovarian function and that serum IL-6 is increased in DOR and POI patients. Our findings confirm that IL-6 is a key molecule mediating PM_{2.5}-induced ovarian injury, suggesting that it may serve as a predictive marker and therapy target for ovarian impairment (see the schematic diagram of this study in Fig. 8).

Over the past decades, rapid industrialization and urbanization have brought about unavoidable environmental problems. The annual average PM_{2.5} concentration in China in 2021 was 31 $\mu\text{g}/\text{m}^3$, which meets China's annual average PM_{2.5} standard (35 $\mu\text{g}/\text{m}^3$) but below the World Health Organization air quality standard (annual average of 5 $\mu\text{g}/\text{m}^3$). In the present study, we simulated exposure to PM_{2.5} at 35 $\mu\text{g}/\text{m}^3$ to identify the cumulative results of sustained PM_{2.5} exposure on ovarian function under relatively good air conditions. Our work demonstrates that PM_{2.5} exposure induces ovarian reserve decline and endocrine dysfunction. These results can serve as a reference for formulating air quality standards.

PM_{2.5} primarily comprises insoluble carbon black particles, adsorbed organic matter, inorganic salts, and heavy metals. A study by Li et al. used fluorescent polystyrene latex microspheres to simulate PM_{2.5} carbon particles and observed their deposition in the lungs and extrapulmonary organs, which showed a nonuniform deposition pattern. At extremely high levels of particle exposure (1,750 $\mu\text{g}/\text{m}^3$), only single particles were observed in the kidney and liver (organs with abundant blood flow) [36]. However, no direct evidence currently supports the deposition




Fig. 4. IL-6 affected testosterone synthesis in theca-interstitial cells (TICs) through the peroxisome proliferator-activated receptor γ (PPAR γ) pathway. (A) Uniform manifold approximation and projection (UMAP) plot and dot plot of IL-6R α expression in identified cell populations in the murine single-cell dataset. (B) Representative images of anti-IL-6R α staining in murine ovaries. (C) The testosterone level in the medium of TICs treated with graded concentrations of rm IL-6 ($n = 6$ biological replicates/group, one-way ANOVA). (D) Top 10 pathways of down-regulated genes by Kyoto Encyclopedia of Genes and Genomes (KEGG) in TICs treated with 50 ng/ml rm IL-6. (E) Relative messenger RNA (mRNA) expression of genes related to the peroxisome proliferator-activated receptor (PPAR) pathway in TICs treated with rm IL-6 ($n = 3$ biological replicates/group, 2-tailed Student t test). (F to H) Protein expression of PPAR γ in TICs treated with rm IL-6 detected by Western blot ($n = 3$ biological replicates/group, 2-tailed Student t test). (I to K) Protein expression of PPAR γ in ovaries from mice treated with rm IL-6 detected by Western blot ($n = 3$ biological replicates/group, 2-tailed Student t test). (L) The testosterone level in the medium of TICs treated with rm IL-6 combined with or without the PPAR γ agonist GW1929 ($n = 5$ biological replicates/group, one-way ANOVA). (M and N) Protein expression of hormone-synthesis-related genes in TICs treated with rm IL-6 combined with or without GW1929 detected by Western blot ($n = 3$ biological replicates/group, one-way ANOVA). * $P < 0.05$. GW, PPAR γ agonist GW1929.




Fig. 5. IL-6 decreased granulosa cell (GC) estradiol synthesis and restricted follicular growth through TICs. (A) Scheme of the experiment on GC intervention. In brief, TICs were pretreated with 50 ng/ml rm IL-6 with or without GW1929 for 24 h. Afterward, they were washed thrice with phosphate-buffered saline (PBS) and incubated in a complete medium without IL-6 or GW1929 for another 24 h. Culture supernatants from the TICs were collected and used as a conditioned medium for GC culture. (B) The estradiol level in the culture supernatants of GCs treated with conditioned medium ($n = 5$ biological replicates/group, one-way ANOVA). (C and D) Protein expression of hormone-synthesis-related genes and apoptosis-related genes in GCs treated with a conditioned medium detected by Western blot ($n = 3$ biological replicates/group, one-way ANOVA). (E and F) Apoptosis of GCs treated with a conditioned medium detected by flow cytometry ($n = 3$ biological replicates/group, one-way ANOVA). (G) Scheme of the experiment on follicular intervention. In brief, TICs were pretreated with 50 ng/ml rm IL-6 with or without GW1929 for 24 h. Afterward, they were washed thrice with PBS and incubated in a complete medium without IL-6 or GW1929 for another 24 h. Culture supernatants from the TICs were collected and used as a conditioned medium for follicle culture. (H) Representative images of follicles treated with a conditioned medium. (I) The diameter of follicles treated with a conditioned medium ($n = 3$ biological replicates/group, 2-way ANOVA). (J) The atresia ratio of follicles treated with a conditioned medium ($n = 3$ biological replicates/group, one-way ANOVA). * $P < 0.05$.




Fig. 6. IL-6-neutralizing antibody alleviated PM_{2.5}-induced ovarian injury. (A) Scheme of the animal study for assessing whether IL-6-neutralizing antibodies can reverse PM_{2.5}-induced ovarian injury. (B) The serum IL-6 level of mice exposed to PM_{2.5} with or without IL-6 antibody administration ($n = 8$ to 10 mice/group, one-way ANOVA). (C) The serum AMH level of mice exposed to PM_{2.5} with or without IL-6 antibody administration ($n = 7$ to 9 mice/group, one-way ANOVA). (D) Ovarian H&E staining images of mice exposed to PM_{2.5} with or without IL-6 antibody administration. (E) Follicle counting results according to ovary serial sections ($n = 5$ mice/group, one-way ANOVA). (F) The proportion of regular or irregular estrous cycles of mice exposed to PM_{2.5} with or without IL-6 antibody administration ($n = 11$ mice/group, chi-square test). (G to I) The serum hormone level of mice exposed to PM_{2.5} with or without IL-6 antibody administration ($n = 8$ to 11 mice/group, one-way ANOVA). (J to N) Protein expression of hormone-synthesis-related genes in ovaries from mice exposed to PM_{2.5} with or without IL-6 antibody administration detected by Western blot ($n = 3$ biological replicates/group, one-way ANOVA).




Fig. 7. Circulating IL-6 levels correlated with ovarian function in women. (A) Scheme of the population study for assessing the association between circulating IL-6 levels and ovarian function. (B to E) Relationship between serum IL-6 levels and serum levels of AMH, E2, T, and FSH ($n = 215$ participants, Pearson test). (F) Serum IL-6 levels in participants ($n = 118$ participants for healthy women, $n = 50$ participants for DOR women, $n = 47$ patients for POI women, one-way ANOVA). DOR, diminished ovarian reserve; POI, premature ovarian insufficiency.

of $PM_{2.5}$ in ovarian tissues. Compounding this issue is the limited blood flow to the ovaries, which renders existing methodologies inadequate for observing the quantity and real-time deposition of $PM_{2.5}$ during typical exposure patterns. Our previous findings have indicated that $PM_{2.5}$ induces IL-6 expression in GCs through the nuclear factor kappa B/IL-6 signaling pathway, which further lead to ovarian injury [20]. However, the direct effects of $PM_{2.5}$ on the cumulus cell–oocyte complex are insufficient to comprehensively account for the ovarian injury. Systemic inflammation has been closely linked to ovarian function [24,25]. Thus, we assume that systemic factors may play a crucial role in ovarian injury caused by $PM_{2.5}$ exposure. Our findings demonstrated that $PM_{2.5}$ exposure induced a systemic inflammatory response, which resulted in elevated levels of circulating IL-6 and keratinocyte-derived chemokine, with IL-6 exhibiting the most pronounced elevation. Furthermore, an analysis of circulating IL-6 levels in women revealed a negative correlation with indicators of ovarian function. Furthermore, rm IL-6 induced ovarian damage, and IL-6 Abs successfully alleviated $PM_{2.5}$ -induced ovarian damage. These findings confirmed the critical role of the circulating IL-6 in mediating $PM_{2.5}$ -induced ovarian injury.

Additionally, we explored the sources of circulating IL-6. IL-6 can be secreted by various immune cells, such as monocytes, macrophages, lymphocytes, mast cells, and dendritic cells, as well as nonimmune cells, including fibroblasts, endothelial cells, adipocytes, and keratinocytes [37,38]. Unlike other cytokines, IL-6 can exert its effects far away from its source, depending on the level of the circulating IL-6. Previous studies have shown that short-term $PM_{2.5}$ exposure induces IL-6 secretion by alveolar macrophages, which leads to elevated circulating IL-6 levels. The clearance of alveolar macrophages reverses the elevated circulating IL-6 levels and thrombosis caused by

$PM_{2.5}$ exposure [27–29]. However, in our study, the clearance of alveolar macrophages neither alleviated the $PM_{2.5}$ -induced increase in circulating IL-6 levels nor improved ovarian function, suggesting that alveolar macrophages are not the primary source of circulating IL-6 in this long-term exposure model. The inconsistency may be due to differences in $PM_{2.5}$ composition, exposure dose, and exposure time. First, the $PM_{2.5}$ particles used in our study were collected in Wuhan, China, while Budinger's group's studies were conducted in Chicago [27,28]. The composition of $PM_{2.5}$ varies from region to region [39,40]. Second, the dose explored in this study was equivalent to a human exposure concentration of $35 \mu\text{g}/\text{m}^3$, while the exposure concentrations were 109.1 ± 6.18 and $118.3 \pm 5.21 \mu\text{g}/\text{m}^3$ in Budinger's group's studies [27,29]. Finally, mice were exposed to $PM_{2.5}$ for 4 weeks in this study, while the exposure period was 24 h in the studies mentioned above [27–29]. The chronic and acute exposure patterns likely result in different responses of immune cells to $PM_{2.5}$.

We further explored the mechanisms by which IL-6 mediates ovarian injury caused by $PM_{2.5}$. Although IL-6 has been extensively studied in autoimmune diseases, infections, and tumors [41], little research has been conducted on its role in ovarian function. Suriyakalaa et al. [42] showed that IL-6 affects androgen synthesis in bovine TICs by inhibiting the expression of LHCGR, STAR, and CYP17A1. In this study, we found that IL-6 affected the expression of the hormone-synthesis-related genes, which are CYP17A1, HSD17B1, and HSL. RNA sequencing suggested that the down-regulated genes were enriched in the PPAR pathway. PPAR γ , a nuclear transcription factor, heterodimerizes with the 9-*cis*-retinoic acid receptor (RXR) upon ligand activation and promotes target gene expression by binding to DNA reaction elements. PPAR γ has been proved to regulate the expression of




Fig. 8. The schematic diagram of the study. PM_{2.5} exposure-induced circulating IL-6 elevation targets TICs and impairs their testosterone synthesis via suppressing the PPAR γ pathway, which subsequently restricts estradiol synthesis of granulosa cells and follicular growth. Neutralization of IL-6 effectively ameliorates PM_{2.5}-induced ovarian damage. Circulating IL-6 is negatively correlated with ovarian function in woman, and serum IL-6 is significantly increased in DOR and POI patients.

CYP19A1, HSD3B, and HSD17B [43]. The PPAR γ agonist, GW1929, can increase serum estrogen levels, decrease FSH and luteinizing hormone levels, and reduce ovarian apoptosis by down-regulating BAX expression and up-regulating BCL2 expression in perimenopausal rats [44]. In our study, IL-6 affected the expression of key genes (CYP17A1, HSD17B1, and HSL) involved in hormone synthesis through the down-regulation of the PPAR γ pathway, resulting in decreased hormone synthesis capacity.

Notably, circulating IL-6 levels negatively correlated with ovarian function in women. Previous studies have demonstrated a positive correlation between follicular fluid IL-6 levels and female age, whereas low levels of follicular fluid IL-6 are associated with increased success in in vitro fertilization clinical pregnancies [45]. Circulating IL-6 levels were significantly higher in postmenopausal women than in nonmenopausal women [46]. In addition, circulating IL-6 levels were significantly higher

in patients with premature ovarian failure than in normal controls [25]. Our results revealed that circulating IL-6 levels were negatively associated with serum AMH and T levels and positively associated with serum FSH levels in women. Serum IL-6 levels were significantly higher in patients with DOR or POI than in healthy participants. Moreover, IL-6 Abs ameliorated ovarian injury induced by exposure to PM_{2.5} in mice. Based on the literature and our findings, circulating IL-6 is a predictive biomarker and therapeutic target for ovarian injury.

In summary, our research provides experimental evidence that exposure to PM_{2.5} induces ovarian injury by elevating circulating IL-6, which targets TICs and impairs T synthesis via the PPAR γ pathway, which further affects GC function and follicle development. Alveolar macrophages are not the major source of elevated IL-6. Our results indicate that IL-6 may be a biomarker for premature ovarian aging and a potential target

for the treatment of PM_{2.5}-related ovarian injury. Our findings offer new insights into the understanding of PM_{2.5}-induced ovarian damage, presenting a promising avenue for evaluating ovarian function and developing clinical strategies for alleviating ovarian damage.

Our research findings suggest that serum IL-6 severely impacts ovarian function, with the source of IL-6 likely being diverse. While previous studies have suggested that PM_{2.5} can enhance IL-6 secretion by alveolar macrophages, our study corroborated this observation. Nevertheless, the restoration of ovarian function was not achieved by eliminating alveolar macrophages, suggesting that IL-6 may be produced by various systems. Further investigation is necessary to evaluate the effectiveness of IL-6 antibodies in preventing ovarian damage in nonhuman primates, which has profound implications for future translational research.

Materials and Methods

Human samples

Overall, 118 healthy women with normal ovarian function, 50 patients with DOR, and 47 patients with POI were recruited from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China) between 2019 and 2022. Healthy women had regular menses and normal serum ovarian steroid hormone levels. The patients with DOR met the following diagnostic criteria: a decrease in the number and/or quality of oocytes in the ovary and/or a decrease in the level of AMH (<1.1 ng/ml) and/or a decrease in AFC (<6) and/or an increase in the level of basal FSH (>10 U/l). The patients with POI met the diagnostic criteria for POI: (a) age < 40 years, with amenorrhea or scanty menstruation \geq 4 months, with or without hypoestrogenic symptoms (hot flashes, palpitation, and insomnia), and (b) 2 serum FSH measurements >25 U/l, taken at an interval of >4 weeks. Both criteria must be satisfied simultaneously. The exclusion criteria were malignant tumors, severe infection, severe liver or kidney dysfunction, prior removal of the uterus or ovary, and use of medications known to affect the immune status or serum levels of ovarian steroid hormones, including oral contraceptives, lipid-lowering agents, antihypertensive drugs, functional foods, and vitamin or mineral supplementation. This study was approved by the ethics committee of Tongji Hospital (No. TJ-IRB20210319). Written informed consent was obtained from all participants at enrollment.

Animals

Female C57BL/6 mice (8 weeks old) were purchased from GemPharmatech (China) and fed ad libitum for 1 week for environmental acclimation. All mice were maintained in specific-pathogen-free conditions with filtered air at a constant temperature of 22 ± 2 °C and a relative humidity of $55\% \pm 10\%$ with a 12:12 h light:dark cycle throughout the study. All animal studies were conducted in accordance with the principles of laboratory animal care.

Ethics statement

All animal procedures and protocols were approved by the ethics committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology of the People's Republic of China (No. TJH-202201023).

PM_{2.5} collection

PM_{2.5} was gathered by Teflon membrane filters (Whatman, USA) with a PM_{2.5} air sampler (TH-150D, Tianhong, Wuhan, China) in Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China (114.12119°E, 30.542089°N) and was extracted from the Teflon membrane filters using the methodology of previous studies [47,48]. Briefly, to scatter the PM_{2.5}, the filters were ultrasonicated for 30 min with a sonicator (KQ-700 V, Shumei, China) in deionized water (18 M Ω /cm). Subsequently, the suspensions were freeze-dried to form PM_{2.5} powder. The PM_{2.5} sample was stored at -80 °C for later use.

Exposure to PM_{2.5}

The objective of this study was to evaluate the effects of PM_{2.5} exposure on ovarian function. Two groups of C57BL/6 mice (22 mice per group) were used for the animal experiments. The mice in the CON group were treated with vehicle (saline), while those in the PM group were treated with PM_{2.5} suspension (8 mg/kg bw) via intratracheal instillation every 2 d. The PM_{2.5} exposure dose was calculated based on the physiological parameters of the mice. The tidal volume of the mice was approximately 0.15 ml, and the respiratory rate was approximately 150 breaths/min. Therefore, the respiratory volume of the mice was approximately 32.4 l/d ($0.15 \text{ ml} \times 150 \text{ breaths/min} \times 60 \text{ min} \times 24 \text{ h} = 32.4 \text{ l}$). Based on the annual average standard of PM_{2.5} in China ($35 \mu\text{g}/\text{m}^3$), the exposure dose of PM_{2.5} was estimated to be $0.7938 \mu\text{g}/\text{d}$ ($32.4 \text{ l} \times 35 \mu\text{g}/\text{m}^3 \times 70\% = 0.7938 \mu\text{g}$), because approximately 70% of inhaled PM_{2.5} is deposited in the deep airways [49,50]. Taking into account a 100-fold uncertainty factor [51,52], an intervention concentration of 8 mg/kg bw PM_{2.5} was set for this experiment ($0.7938 \mu\text{g} \times 100 \times 2 \text{ d} \div 20 \text{ g} = 7.938 \text{ mg/kg bw} \approx 8 \text{ mg/kg bw}$), which is in line with the doses used in previous studies [20,53]. After 4 weeks of exposure, blood samples were collected from the angular vein, and the mice were sacrificed. Six ovaries were fixed in 4% paraformaldehyde at 4 °C. The remaining ovaries were stored in liquid nitrogen for further messenger RNA or protein detection.

rm IL-6 treatment

This study investigated the correlation between circulating IL-6 levels and ovarian injury. Two groups of C57BL/6 mice were used in the animal experiments (16 mice per group). The CON group received vehicle treatment (normal saline), whereas the experimental group (rm IL-6) received rm IL-6 (400 ng/mouse, HY-P7063, MedChemExpress, USA) via intraperitoneal injection every 2 d. The treatment duration for both groups was 4 weeks.

Clodronate liposome treatment

This study determined whether circulating IL-6 originates from alveolar macrophages. This batch of animal experiments included 4 groups, each consisting of 16 C57BL/6 mice. The groups consisted of the following treatments: mice treated with vehicle (normal saline) as the CON group, mice treated with PM_{2.5} suspension (8 mg/kg bw) by intratracheal instillation every 2 d (PM), mice treated with PM_{2.5} suspension (8 mg/kg bw) every 2 d and clodronate liposomes (50 μ l/mouse, C-005, LIPOSOMA, Netherlands) every 4 d by intratracheal instillation (PM + CLS), and mice treated with clodronate liposomes (50 μ l/mouse) by intratracheal instillation every 4 d (CLS). The mice were treated for 4 weeks.

IL-6 Ab treatment

This study aimed to explore whether IL-6 Abs could alleviate PM_{2.5}-induced ovarian injury. The commercial antimouse IL-6 Ab has been extensively validated in preclinical mouse studies [54–57]. This batch of animal experiments included 4 groups, 16 C57BL/6 mice per group. The mice were treated with vehicle (normal saline) (CON group), PM_{2.5} suspension (8 mg/kg bw) by intratracheal instillation every 2 d (PM), PM_{2.5} suspension (8 mg/kg bw) by intratracheal instillation every 2 d and IL-6 antibodies (100 µg/mouse, A2118, Selleck, USA) by intraperitoneal injection twice a week (PM + IL-6 Ab), and PM_{2.5} suspension (8 mg/kg bw) by intratracheal instillation every 2 d and immunoglobulin G (IgG) isotype (100 µg/mouse, A2119, Selleck, USA) by intraperitoneal injection twice a week (PM + IgG). The treatment duration for all groups was 4 weeks.

Bronchoalveolar lavage fluid collection

Mice were secured in the supine position on the operating table after anesthesia. The skin on the neck and chest was disinfected using 75% alcohol. The trachea was exposed by cutting off the sternum after a cut on the neck skin. An approximately 0.2-cm-long incision was then made obliquely in the proximal part of the trachea. The medical indwelling needle was inserted into an approximately 1-cm-deep proximal part, and the incision was ligated and fixed using silk threads. Subsequently, the lungs were lavaged with 0.5 ml of cold phosphate-buffered saline (PBS) for 3 cycles each. Subsequently, 1 ml of bronchoalveolar lavage fluid was fully recycled. To measure the IL-6 levels, the supernatant was centrifuged and aspirated.

Isolation and culture of GCs and TICs

Mouse GCs and TICs were collected by gently puncturing the preantral follicles from 21- to 23-d-old mice using a 25-G syringe needle, as previously described [58]. TICs were pre-treated with graded concentrations of rm IL-6 (0 to 50 ng/ml, HY-P7063, MedChemExpress, USA) for 24 h. Afterward, they were washed thrice with PBS and incubated in a complete medium without IL-6 for another 24 h. Culture supernatants from the TICs were collected and used for GC culture.

Isolation and culture of prenatal follicles

Follicle culture methods have been described previously [59]. The ovaries of 2-week-old mice were removed by blunt dissection in L15 medium (PYG-0038, Boster, Wuhan, China). Following mechanical dissection using 2 syringe needles, only the follicles with an intact basal membrane, central and spherical oocytes, and intact GCs were selected for follicle culture in 100 µl of culture medium at 37 °C and 5% CO₂. For the follicle culture, the conditioned medium from TICs was used. Refreshments were performed every other day by removing and replacing 50 µl of the medium. Before the medium refreshment, photographs of every follicle were taken using an inverted microscope (Olympus, Tokyo, Japan).

Estrous cycle detection

Vaginal smears were collected every morning at 0900 for 14 consecutive days using 10 µl of normal saline placed on glass slides. The slides were stained with H&E before microscopic examination to determine the cell cycle phase.

Follicle counting

The ovaries were fixed in 4% paraformaldehyde overnight, dehydrated in an ethanol gradient, and embedded in paraffin.

Serial sections of 4-µm thickness were then obtained. The 4 sections were mounted on glass slides. H&E staining was performed on every fourth slide. Two individuals, blinded to the origin of the sections, analyzed the stained slides under a microscope. Only the follicles containing oocytes were included in the follicle count. This procedure is based on previous descriptions [20,60].

Enzyme-linked immune sorbent assay

Blood samples were collected during estrus. The levels of AMH, E2, T, and FSH were measured by enzyme-linked immune sorbent assay according to the manufacturer's instructions (CSB-E13156m, CSB-E05109, CSB-E05101, and CSB-E06871, Cusabio, China). IL-6 levels were measured using enzyme-linked immune sorbent assay according to the manufacturer's instructions (E-EL-M0044, Elabscience, China).

Luminex liquid suspension chip detection

Cytokines in the circulation and ovarian tissues were detected using the Luminex liquid suspension chip detection technology offered by Wayen Biotechnologies (Shanghai, China). The Bio-Plex Pro Mouse Cytokine GrpI Panel 23-plex kit was used according to the manufacturer's instructions. Briefly, murine serum or ovarian tissue homogenates were incubated in 96-well plates containing the microbeads for 1 h. The detection antibody was then added and incubated for 30 min. Streptavidin-phycoerythrin was then added to each well and incubated for 10 min. Finally, the Bio-Plex MAGPIX System (Bio-Rad) was used to read the values.

Western blot

Ovaries and cells were harvested and lysed in a radioimmuno-precipitation assay buffer. polyvinylidene fluoride membranes were incubated with different primary antibodies such as β-actin (1:5,000, AC004, ABclonal, China), glyceraldehyde-3-phosphate dehydrogenase (1:5,000, AC002, ABclonal, China), HSD3B1 (1:1,000, A19266, ABclonal, China), CYP11A1 (1:1,000, A23954, ABclonal, China), CYP17A1 (1:1,000, A5067, ABclonal, China), CYP19A1 (1:1,000, 16554-1-AP, Proteintech, China), HSD17B1 (1:1,000, A10839, ABclonal, China), NR1H3 (1:1,000, A3974, ABclonal, China), HMGCR (1:1,000, A19063, ABclonal, China), HMGCS1 (1:1,000, A3916, ABclonal, China), SR-B1 (1:1,000, A0827, ABclonal, China), HSL (1:1,000, A24689, ABclonal, China), and IL-6 (1:1,000, 12912, Cell Signaling Technology, USA) overnight at 4 °C. Afterward, the membranes were incubated with the secondary antibody, horseradish peroxidase-conjugated goat antirabbit IgG (H + L) (1:3,000, GB23303, Servicebio, China) for 30 min at 37 °C. The relative amounts of proteins were quantified using Image Lab software (Bio-Rad, USA). β-Actin or glyceraldehyde-3-phosphate dehydrogenase was used as an internal control.

Immunohistochemistry

The expression of IL-6Rα in ovaries and F4/80, CD3, and CD19 in lungs was detected by IHC staining. Sections were incubated overnight at 4 °C with primary antibodies IL-6Rα (1:100, ab300581, Abcam, USA), F4/80 (1:200, 70076, Cell Signaling Technology, USA), CD3 (1:200, 78588, Cell Signaling Technology, USA), and CD19 (1:200, 90176, Cell Signaling Technology, USA). The following day, sections were rinsed with PBS and incubated with the secondary antibody for 1 h at 37 °C. To visualize IL-6Rα-, F4/80-, CD3-, and CD19-positive cells, diaminobenzidine (G1212-200T, Servicebio, China) was used.

Transmission electron microscopy

Ovarian samples were prepared for TEM analysis, as previously described [61]. Samples were dehydrated using a series of ascending ethanol concentrations, fixed in osmium tetroxide, and embedded in epoxy resin. Images were captured using an 80-kV TEM instrument (CM 10, Philips, Netherlands).

Quantitative real-time polymerase chain reactions

Total RNA was extracted using the TRIzol reagent (15596018CN, Invitrogen, USA). Reverse transcription kits (R423-01, Vazyme, Nanjing, China) were used to convert 1 µg of RNA into complementary DNA. Quantitative PCR was conducted using ChamQ Universal SYBR qPCR Master Mix (Q711-02, Vazyme, China) in a CFX96 real-time PCR system (Bio-Rad, USA). The messenger RNA expression level of target genes was calculated using the $2^{-\Delta\Delta Ct}$. The primer sequences are listed in Table S1.

Cell apoptosis detection by flow cytometry

Apoptosis in GCs was detected by flow cytometry using FITC-Annexin V Apoptosis Detection Kit I (556547, BD Pharmingen, USA), following the manufacturer's instructions. GCs were harvested using trypsin and washed twice with PBS. Subsequently, the cells were incubated with annexin V-propidium iodide for 15 min. Flow cytometry was performed using a flow cytometer to determine the population of annexin V-positive cells (BD Pharmingen). The percentage of apoptotic cells in the upper and lower right quadrants was calculated.

Uniform manifold approximation and projection analysis

Murine single-cell RNA sequencing was conducted by our research team. Raw sequencing and processed data are available in the National Center for Biotechnology Information Gene Expression Omnibus under the accession number "GSE241318". A dimensional reduction plot displaying the distribution of IL-6R α expression was made using the "FeaturePlot" function of the Seurat package.

Statistical analysis

The experiments described above were repeated at least thrice, except for the animal experiments. Values are expressed as mean \pm standard error of the mean unless noted otherwise. The Q-Q plot and the Shapiro-Wilk test were combined to test the normality of the data using SPSS 24. Statistical significance was assessed using a 2-tailed Student *t* test, a chi-square test, and one-way or 2-way analysis of variance using the GraphPad Prism 7 software. Pearson's correlation coefficients were used to examine the relationship between serum IL-6 and ovarian steroid hormone levels in women. $P < 0.05$ was considered statistically significant.

Acknowledgments

The authors thank the Experimental Medicine Center of Tongji Hospital, Tongji Medical School, Huazhong University of Science and Technology, for the advanced experimental instruments.

Funding: This work was supported by the National Key Research and Development Program of China (2022YFC2704100), the Major Program of National Natural Science Foundation of China (91643206), the National Natural Science Foundation of China (82371648 and 82301849), and the Nature Science Foundation of Hubei Province (No. 2022CFB502).

Author contributions: Y.C., J.Z., and S.W. conceived the study. Y.C., S.Z., and Y.X. performed the experiments. Y.C., T.W., and M.L. performed the bioinformatics and statistical analysis. Y.C., J.Z., T.Z., and Yaling Wu prepared the figure, discussed the results and wrote the manuscript. Jinjin Zhang, Tianyu Zhang, Y.W., Y.L., M.W., and S.W. revised the manuscript. All authors approved the manuscript.

Competing interests: The authors declare that they have no competing interests.

Data Availability

All data are available in the main text or the supplementary materials.

Supplementary Materials

Figs. S1 to S3
Table S1

References

- Chen Y, Cao J, Zhao J, Xu H, Arimoto R, Wang G, Han Y, Shen Z, Li G. *n*-Alkanes and polycyclic aromatic hydrocarbons in total suspended particulates from the southeastern Tibetan Plateau: Concentrations, seasonal variations, and sources. *Sci Total Environ.* 2014;470–471:9–18.
- Kholodov AS, Tarasenko IA, Zinkova EA, Teodoro M, Docea AO, Calina D, Tsatsakis A, Golokhvast KS. The study of airborne particulate matter in Dalnegorsk Town. *Int J Environ Res Public Health.* 2021;18(17):Article 9234.
- Loomis D, Grosse Y, Lauby-Secretan B, Ghissassi FE, Bouvard V, Benbrahim-Tallaa L, Guha N, Baan R, Mattock H, Straif K. The carcinogenicity of outdoor air pollution. *Lancet Oncol.* 2013;14(13):1262–1263.
- Southerland VA, Brauer M, Mohegh A, Hammer MS, van Donkelaar A, Martin RV, Apte JS, Anenberg SC. Global urban temporal trends in fine particulate matter (PM_{2.5}) and attributable health burdens: Estimates from global datasets. *Lancet Planet Health.* 2022;6(2):e139–e146.
- Zhao C, Wang Y, Su Z, Pu W, Niu M, Song S, Wei L, Ding Y, Xu L, Tian M, et al. Respiratory exposure to PM_{2.5} soluble extract disrupts mucosal barrier function and promotes the development of experimental asthma. *Sci Total Environ.* 2020;730:Article 139145.
- Lo WC, Ho CC, Tseng E, Hwang JS, Chan CC, Lin HH. Long-term exposure to ambient fine particulate matter (PM_{2.5}) and associations with cardiopulmonary diseases and lung cancer in Taiwan: A nationwide longitudinal cohort study. *Int J Epidemiol.* 2022;51(4):1230–1242.
- Hayes RB, Lim C, Zhang Y, Cromar K, Shao Y, Reynolds HR, Silverman DT, Jones RR, Park Y, Jerrett M, et al. PM_{2.5} air pollution and cause-specific cardiovascular disease mortality. *Int J Epidemiol.* 2020;49:25–35.
- Shah AS, Lee KK, McAllister DA, Hunter A, Nair H, Whiteley W, Langrish JP, Newby DE, Mills NL. Short term exposure to air pollution and stroke: Systematic review and meta-analysis. *BMJ.* 2015;350:Article h1295.
- Wang BR, Shi JQ, Ge NN, Ou Z, Tian YY, Jiang T, Zhou JS, Xu J, Zhang YD. PM_{2.5} exposure aggravates oligomeric amyloid beta-induced neuronal injury and promotes NLRP3 inflammasome activation in an in vitro model

- of Alzheimer's disease. *J Neuroinflammation*. 2018;15: Article 132.
10. Li CY, Wu CD, Pan WC, Chen YC, Su HJ. Association between long-term exposure to PM_{2.5} and incidence of type 2 diabetes in Taiwan: A national retrospective cohort study. *Epidemiology*. 2019;30:S67–S75.
 11. Tamayo-Ortiz M, Téllez-Rojo MM, Rothenberg SJ, Gutiérrez-Avila I, Just AC, Kloog I, Texcalac-Sangrador JL, Romero-Martinez M, Bautista-Arredondo LF, Schwartz J, et al. Exposure to PM_{2.5} and obesity prevalence in the Greater Mexico City area. *Int J Environ Res Public Health*. 2021;18(5):Article 2301.
 12. Tong J, Ren Y, Liu F, Liang F, Tang X, Huang D, An X, Liang X. The impact of PM_{2.5} on the growth curves of children's obesity indexes: A prospective cohort study. *Front Public Health*. 2022;10:Article 843622.
 13. Mohallem SV, de Araújo Lobo DJ, Pesquero CR, Assunção JV, de Andre PA, Saldiva PH, Dolhnikoff M. Decreased fertility in mice exposed to environmental air pollution in the city of Sao Paulo. *Environ Res*. 2005;98(2):196–202.
 14. Mahalingaiah S, Hart JE, Laden F, Farland LV, Hewlett MM, Chavarro J, Aschengrau A, Missmer SA. Adult air pollution exposure and risk of infertility in the Nurses' Health Study II. *Hum Reprod*. 2016;31(3):638–647.
 15. Malley CS, Kuylensstierna JCI, Vallack HW, Henze DK, Blencowe H, Ashmore MR. Preterm birth associated with maternal fine particulate matter exposure: A global, regional and national assessment. *Environ Int*. 2017;101:173–182.
 16. Wang K, Tian Y, Zheng H, Shan S, Zhao X, Liu C. Maternal exposure to ambient fine particulate matter and risk of premature rupture of membranes in Wuhan, Central China: A cohort study. *Environ Health*. 2019;18(1):Article 96.
 17. Li H, Hart JE, Mahalingaiah S, Nethery RC, Bertone-Johnson E, Laden F. Long-term exposure to particulate matter and roadway proximity with age at natural menopause in the Nurses' Health Study II Cohort. *Environ Pollut*. 2021;269:Article 116216.
 18. Gaskins AJ, Mínguez-Alarcón L, Fong KC, Abdelmessih S, Coull BA, Chavarro JE, Schwartz J, Kloog I, Souter I, Hauser R, et al. Exposure to fine particulate matter and ovarian reserve among women from a fertility clinic. *Epidemiology*. 2019;30(4):486–491.
 19. Xia L, Zhang C, Li D, Yang L, Sun W, Cai S, Meng Q, Shen J, Wang Y, Xu M. Fuel fine particulate matter induces ovary dysfunction via metal elements imbalance and steroid biosynthesis signaling pathway inhibition. *Environ Sci Technol Lett*. 2018;6(1):26–33.
 20. Zhou S, Xi Y, Chen Y, Zhang Z, Wu C, Yan W, Luo A, Wu T, Zhang J, Wu M, et al. Ovarian dysfunction induced by chronic whole-body PM_{2.5} exposure. *Small*. 2020;16(33):Article e2000845.
 21. Han B, Xu J, Zhang Y, Li P, Li K, Zhang N, Han J, Gao S, Wang X, Geng C, et al. Associations of exposure to fine particulate matter mass and constituents with systemic inflammation: A cross-sectional study of urban older adults in China. *Environ Sci Technol*. 2022;56(11):7244–7255.
 22. Guan L, Geng X, Stone C, Cosky EEP, Ji Y, Du H, Zhang K, Sun Q, Ding Y. PM_{2.5} exposure induces systemic inflammation and oxidative stress in an intracranial atherosclerosis rat model. *Environ Toxicol*. 2019;34(4):530–538.
 23. Siponen T, Yli-Tuomi T, Aurela M, Dufva H, Hillamo R, Hirvonen MR, Huttunen K, Pekkanen J, Pennanen A, Salonen I, et al. Source-specific fine particulate air pollution and systemic inflammation in ischaemic heart disease patients. *Occup Environ Med*. 2015;72(4):277–283.
 24. Şenates E, Çolak Y, Erdem ED, Yeşil A, Coşkunpinar E, Şahin Ö, Altunöz ME, Tuncer I, Kurdaş Övünç AO. Serum anti-Müllerian hormone levels are lower in reproductive-age women with Crohn's disease compared to healthy control women. *J Crohns Colitis*. 2013;7(2):e29–e34.
 25. Sun S, Chen H, Zheng X, Ma C, Yue R. Analysis on the level of IL-6, IL-21, AMH in patients with auto-immunity premature ovarian failure and study of correlation. *Exp Ther Med*. 2018;16(4):3395–3398.
 26. Miller WL, Bose HS. Early steps in steroidogenesis: Intracellular cholesterol trafficking. *J Lipid Res*. 2011;52(12):2111–2135.
 27. Chiarella SE, Soberanes S, Urich D, Morales-Nebreda L, Nigdelioglul R, Green D, Young JB, Gonzalez A, Rosario C, Misharin AV, et al. β_2 -Adrenergic agonists augment air pollution-induced IL-6 release and thrombosis. *J Clin Invest*. 2014;124(7):2935–2946.
 28. Mutlu GM, Green D, Bellmeyer A, Baker CM, Burgess Z, Rajamannan N, Christman JW, Foiles N, Kamp DW, Ghio AJ, et al. Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway. *J Clin Invest*. 2007;117(10):2952–2961.
 29. Soberanes S, Misharin AV, Jairaman A, Morales-Nebreda L, McQuattie-Pimentel AC, Cho T, Hamanaka RB, Meliton AY, Reyfman PA, Walter JM, et al. Metformin targets mitochondrial electron transport to reduce air-pollution-induced thrombosis. *Cell Metab*. 2019;29(2):355–347.e5.
 30. Michael S, Montag M, Dott W. Pro-inflammatory effects and oxidative stress in lung macrophages and epithelial cells induced by ambient particulate matter. *Environ Pollut*. 2013;183:19–29.
 31. Chan LS, Wells RA. Cross-talk between PPARs and the partners of RXR: A molecular perspective. *PPAR Res*. 2009;2009:Article 925309.
 32. Chen N, Xu X, Guo Y, Zhao M, Li Y, Zhou T, Zhang X, Gao J, Zhu F, Guo C, et al. Brain short-chain fatty acids induce ACS2 to ameliorate depressive-like behavior via PPAR γ -TPH2 axis. *Research*. 2024;7:Article 0400.
 33. Chen MH, Li T, Ding CH, Xu YW, Guo LY, Zhou CQ. Growth differential factor-9 inhibits testosterone production in mouse theca interstitial cells. *Fertil Steril*. 2013;100(5):1444–1450.
 34. Izquierdo D, Foyouzi N, Kwintkiewicz J, Duleba AJ. Mevastatin inhibits ovarian theca-interstitial cell proliferation and steroidogenesis. *Fertil Steril*. 2004;82(Suppl 3):1193–1197.
 35. Rice BF. Steroid synthesis by the human ovary: A compartmental viewpoint. *Med Clin North Am*. 1967;51(4):903–913.
 36. Li D, Li Y, Li G, Zhang Y, Li J, Chen H. Fluorescent reconstitution on deposition of PM_{2.5} in lung and extrapulmonary organs. *Proc Natl Acad Sci USA*. 2019;116(7):2488–2493.
 37. Papanicolaou DA, Vgontzas AN. Interleukin-6: The endocrine cytokine. *J Clin Endocrinol Metab*. 2000;85(3):1331–1333.
 38. Qing H, Desrouleaux R, Israni-Winger K, Mineur YS, Fogelman N, Zhang C, Rashed S, Palm NW, Sinha R, Picciotto MR, et al. Origin and function of stress-induced IL-6 in murine models. *Cell*. 2020;182(2):372–387.e14.
 39. Luglio DG, Katsigeorgis M, Hess J, Kim R, Adragna J, Raja A, Gordon C, Fine J, Thurston G, Gordon T, et al.

- PM_{2.5} concentration and composition in subway systems in the northeastern United States. *Environ Health Perspect*. 2021;129(2):Article 27001.
40. Trusz A, Ghazal H, Piekarska K. Seasonal variability of chemical composition and mutagenic effect of organic PM_{2.5} pollutants collected in the urban area of Wrocław (Poland). *Sci Total Environ*. 2020;733:Article 138911.
 41. Hirano T. IL-6 in inflammation, autoimmunity and cancer. *Int Immunol*. 2021;33(3):127–148.
 42. Samir M, Glister C, Mattar D, Laird M, Knight PG. Follicular expression of pro-inflammatory cytokines tumour necrosis factor- α (TNF α), interleukin 6 (IL6) and their receptors in cattle: TNF α , IL6 and macrophages suppress thecal androgen production in vitro. *Reproduction*. 2017;154(1):35–49.
 43. Suriyakalaa U, Ramachandran R, Doualathunnisa JA, Aseervatham SB, Sankarganesh D, Kamalakkannan S, Kadalmani B, Angayarkanni J, Akbarsha MA, Achiraman S. Upregulation of *Cyp19a1* and *PPAR- γ* in ovarian steroidogenic pathway by *Ficus religiosa*: A potential cure for polycystic ovary syndrome. *J Ethnopharmacol*. 2021;267:Article 113540.
 44. Wang X, Xu K, Xiong Y, Li Q, Zhao X. Effects of GW1929 on uterus, ovary and bone metabolism function in perimenopausal rats. *Am J Transl Res*. 2020;12(5):1884–1893.
 45. Altun T, Jindal S, Greenseid K, Shu J, Pal L. Low follicular fluid IL-6 levels in IVF patients are associated with increased likelihood of clinical pregnancy. *J Assist Reprod Genet*. 2011;28(3):245–251.
 46. Kim OY, Chae JS, Paik JK, Seo HS, Jang Y, Cavaillon J-M, Lee JH. Effects of aging and menopause on serum interleukin-6 levels and peripheral blood mononuclear cell cytokine production in healthy nonobese women. *Age*. 2012;34(2):415–425.
 47. Chen Y, Xi Y, Li M, Wu Y, Yan W, Dai J, Wu M, Ding W, Zhang J, Zhang F, et al. Maternal exposure to PM_{2.5} decreases ovarian reserve in neonatal offspring mice through activating PI3K/AKT/FoxO3a pathway and ROS-dependent NF- κ B pathway. *Toxicology*. 2022;481:Article 153352.
 48. Imrich A, Ning Y, Kobzik L. Insoluble components of concentrated air particles mediate alveolar macrophage responses in vitro. *Toxicol Appl Pharmacol*. 2000;167(2):140–150.
 49. Cassee FR, Muijser H, Duistermaat E, Freijer JJ, Geerse KB, Marijnissen JC, Arts JH. Particle size-dependent total mass deposition in lungs determines inhalation toxicity of cadmium chloride aerosols in rats. Application of a multiple path dosimetry model. *Arch Toxicol*. 2002;76(5–6):277–286.
 50. Hougaard KS, Jensen KA, Nordly P, Taxvig C, Vogel U, Saber AT, Wallin H. Effects of prenatal exposure to diesel exhaust particles on postnatal development, behavior, genotoxicity and inflammation in mice. *Part Fibre Toxicol*. 2008;5:Article 3.
 51. World Health Organization. *Principles for the safety assessment of food additives and contaminants in food*. Geneva (Switzerland): World Health Organization; 1987.
 52. Ren L, Huang J, Wei J, Zang Y, Zhao Y, Wu S, Zhao X, Zhou X, Sun Z, Lu H. Maternal exposure to fine particle matters cause autophagy via UPR-mediated PI3K-mTOR pathway in testicular tissue of adult male mice in offspring. *Ecotoxicol Environ Saf*. 2020;189:Article 109943.
 53. Gai HF, An JX, Qian XY, Wei YJ, Williams JP, Gao GL. Ovarian damages produced by aerosolized fine particulate matter (PM_{2.5}) pollution in mice: Possible protective medications and mechanisms. *Chin Med J*. 2017;130:1400–1410.
 54. Huehnchen P, Muenzfeld H, Boehmerle W, Endres M. Blockade of IL-6 signaling prevents paclitaxel-induced neuropathy in C57Bl/6 mice. *Cell Death Dis*. 2020;11(1): Article 45.
 55. Bonapace L, Coissieux M-M, Wyckoff J, Mertz KD, Varga Z, Jung T, Bentires-Alj M. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. *Nature*. 2014;515(7525):130–133.
 56. Zhao Y, Xiao X, Frank SJ, Lin HY, Xia Y. Distinct mechanisms of induction of hepatic growth hormone resistance by endogenous IL-6, TNF- α , and IL-1 β . *Am J Physiol Endocrinol Metab*. 2014;307(2):E186–E198.
 57. Smith SEP, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. *J Neurosci*. 2007;27(40):10695–10702.
 58. Tian Y, Shen W, Lai Z, Shi L, Yang S, Ding T, Wang S, Luo A. Isolation and identification of ovarian theca-interstitial cells and granulosa cells of immature female mice. *Cell Biol Int*. 2015;39(5):584–590.
 59. Yan W, Zhou S, Shen W, Cheng J, Yuan S, Ye S, Jin Y, Luo A, Wang S. Suppression of SEMA6C promotes preantral follicles atresia with decreased cell junctions in mice ovaries. *J Cell Physiol*. 2019;234(4):4934–4943.
 60. Li M, Zhou S, Wu Y, Li Y, Yan W, Guo Q, Xi Y, Chen Y, Li Y, Wu M, et al. Prenatal exposure to propylparaben at human-relevant doses accelerates ovarian aging in adult mice. *Environ Pollut*. 2021;285:Article 117254.
 61. Shi L, Zhang J, Lai Z, Tian Y, Fang L, Wu M, Xiong J, Qin X, Luo A, Wang S. Long-term moderate oxidative stress decreased ovarian reproductive function by reducing follicle quality and progesterone production. *PLOS ONE*. 2016;11(9): Article e0162194.